Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Primary Sclerosing Cholangitis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2017, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape. Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 8, 2, 6 and 1 respectively. Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Primary Sclerosing Cholangitis - Overview Primary Sclerosing Cholangitis - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Primary Sclerosing Cholangitis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development Acorda Therapeutics Inc Albireo Pharma Inc Allergan Plc Conatus Pharmaceuticals Inc Dr. Falk Pharma GmbH Gilead Sciences Inc iCo Therapeutics Inc. Intercept Pharmaceuticals Inc NGM Biopharmaceuticals Inc Sancilio & Company Inc Seres Therapeutics Inc Shenzhen HighTide Biopharmaceutical Ltd Shire Plc Sirnaomics Inc Primary Sclerosing Cholangitis - Drug Profiles A-4250 - Drug Profile Product Description Mechanism Of Action R&D Progress berberine ursodeoxycholate - Drug Profile Product Description Mechanism Of Action R&D Progress bertilimumab - Drug Profile Product Description Mechanism Of Action R&D Progress Biologic for Metabolic and Gastrointestinal Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress cenicriviroc mesylate - Drug Profile Product Description Mechanism Of Action R&D Progress GS-9674 - Drug Profile Product Description Mechanism Of Action R&D Progress HTD-1801 - Drug Profile Product Description Mechanism Of Action R&D Progress IDN-7314 - Drug Profile Product Description Mechanism Of Action R&D Progress maralixibat chloride - Drug Profile Product Description Mechanism Of Action R&D Progress NGM-282 - Drug Profile Product Description Mechanism Of Action R&D Progress norursodeoxycholic acid - Drug Profile Product Description Mechanism Of Action R&D Progress obeticholic acid - Drug Profile Product Description Mechanism Of Action R&D Progress SC-404 - Drug Profile Product Description Mechanism Of Action R&D Progress SC-435 - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Primary Sclerosing Cholangitis - Drug Profile Product Description Mechanism Of Action R&D Progress STP-705 - Drug Profile Product Description Mechanism Of Action R&D Progress timolumab - Drug Profile Product Description Mechanism Of Action R&D Progress Primary Sclerosing Cholangitis - Dormant Projects Primary Sclerosing Cholangitis - Discontinued Products Primary Sclerosing Cholangitis - Product Development Milestones Featured News & Press Releases Jun 26, 2017: FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC May 19, 2017: Intercept Receives Innovation Award from the National Organization for Rare Disorders for the Development of Ocaliva (obeticholic acid) Mar 02, 2017: NICE Recommends Ocaliva (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern Ireland Jan 05, 2017: Phenex Receives $100 Million Milestone Payment From Gilead Aug 26, 2016: Biotie: BTT1023 Receives Orphan Drug Designation in the United States Jun 07, 2016: Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver Diseases Apr 16, 2016: Investigational treatment provides hope for some chronic liver disease sufferers Jan 07, 2016: Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015 Nov 03, 2015: Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting Mar 31, 2015: Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitis Feb 17, 2015: BTT1023 receives positive opinion for Orphan Drug Designation from COMP Jul 24, 2014: Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding Nov 18, 2013: Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases Sep 26, 2013: Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Primary Sclerosing Cholangitis, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Primary Sclerosing Cholangitis - Pipeline by Acorda Therapeutics Inc, H2 2017 Primary Sclerosing Cholangitis - Pipeline by Albireo Pharma Inc, H2 2017 Primary Sclerosing Cholangitis - Pipeline by Allergan Plc, H2 2017 Primary Sclerosing Cholangitis - Pipeline by Conatus Pharmaceuticals Inc, H2 2017 Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H2 2017 Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences Inc, H2 2017 Primary Sclerosing Cholangitis - Pipeline by iCo Therapeutics Inc., H2 2017 Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals Inc, H2 2017 Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals Inc, H2 2017 Primary Sclerosing Cholangitis - Pipeline by Sancilio & Company Inc, H2 2017 Primary Sclerosing Cholangitis - Pipeline by Seres Therapeutics Inc, H2 2017 Primary Sclerosing Cholangitis - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2017 Primary Sclerosing Cholangitis - Pipeline by Shire Plc, H2 2017 Primary Sclerosing Cholangitis - Pipeline by Sirnaomics Inc, H2 2017 Primary Sclerosing Cholangitis - Dormant Projects, H2 2017 Primary Sclerosing Cholangitis - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
